Cipla stock
CIPLA.NSNSECipla Limited, HealthcareISIN INE059A01026
67Score 67 out of 100, Neutral
Price and trend
69 / 100
Price history
−7.3% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 3.3% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 76).
The price is 8.3% below its 52-week high. Largest decline in 20 years: 49% (August 2015 to March 2020).
Chart figures for advanced users
- SMA 50$14.59
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$14.55
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)76
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$12.73
- The lowest closing price of the last twelve months.
- Resistance$16.39
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Cipla Limited belongs to the Drug Manufacturers (Specialty & Generic) industry (India) and, with a market value of $12.14B, is number 23 of 78 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $3.01B (up 3.3% year on year) and earnings of $414.03M (down 26.4%).
- For fiscal 2027, analysts expect on average revenue of $3.26B (up 8.3%) and adjusted earnings per share of $0.52 (up 1.4%).
Show more
- MEQIRI Score 67 out of 100 (Neutral): rank 181 of 714 in Healthcare, median 53.
- The P/E is 39.3 (Drug Manufacturers (Specialty & Generic) median 32.6, own median of recent years 27.5).
- Our model puts fair value at $15.48, with the price 2% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $1.07B, financial debt $65.51M.Stability 97
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.Fundamentals 82
- Analysts expect strong earnings growthUp 19.9% a year through 2029 (estimates from 32 analysts).
Weaknesses
- Margin fallingOperating margin 16.7%, average of the prior years 37.2% (to 2025).Profitability 62
Its standout strengths are stability and fundamentals, while valuation and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 66 to 67.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $12.90 and expensive above $19.35 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $18.50 (cash-flow model) and $12.46 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 12.6%. At 13.6% the fair value would be $13.92, at 11.6% it would be $17.71.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (32.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 1% on the twelve months before. Revenue has grown solidly since 2007, at about 12% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 43%, operating 17%, net 14%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 22 Jan 2027in 71 days
- Last reported
- 26 Oct 2026EPS reported $0.12 (expected $0.12)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 4.0% since 25 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.52−4.0%
- Revenue
- $3.26B−1.2%
- Earnings per share
- $0.66−2.7%
- Revenue
- $3.69B−0.2%
MEQIRI has stored the estimates since 25 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Cipla
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 67
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Laurus LabsLAURUSLABS.NS $14.01B70
- Elanco Animal HealthELAN $13.23B49
- Zydus LifesciencesZYDUSLIFE.NS $12.77B69
- Dr. Reddy's LaboratoriesRDY $12.25B62
- Zhejiang NHU002001.SZ $11.93B75
- Mankind PharmaMANKIND.NS $11.73B65
- Aurobindo PharmaAUROPHARMA.NS $11.22B68
- LupinLUPIN.NS $9.88B76
ETFs that hold Cipla
Held by 17 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI India UCITS ETFQDV5 | 0.53% | 0.65% | €4.91B |
| iShares Edge MSCI EM Minimum Volatility UCITS ETFEUNZ | 0.43% | 0.40% | €428.84M |
| iShares MSCI EM Consumer Growth UCITS ETFCEMG | 0.23% | 0.60% | €31.52M |
Show 5 more
| Amundi MSCI EM Asia ESG Broad Transition UCITS ETF AccLCUA | 0.18% | 0.25% | €628.34M |
| iShares MSCI EM CTB Enhanced ESG UCITS ETFEDM2 | 0.13% | 0.18% | €7.09B |
| Amundi MSCI Emerging Markets ESG Selection UCITS ETF DR (C)SADM | 0.12% | 0.18% | €1.02B |
| iShares MSCI EM Asia UCITS ETFCEBL | 0.08% | 0.20% | €6.97B |
| Amundi Core MSCI Emerging Markets UCITS ETF EUR DistAEMD | 0.07% | 0.18% | €9.12B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = ₹93.6946)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 10 Jul 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.